The Weight Loss Peptide Landscape
The development of GLP-1 receptor agonists has fundamentally changed weight management. For the first time, pharmacological treatment produces weight loss comparable to bariatric surgery. But the landscape is evolving quickly — with single, dual, and triple-receptor agonists now available, choosing the right one requires understanding the differences.
This guide compares the four most relevant weight loss peptides: semaglutide, tirzepatide, retatrutide, and AOD-9604.
The Master Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide | AOD-9604 |
|---|---|---|---|---|
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound | (Investigational) | (Research chemical) |
| Mechanism | GLP-1 agonist | GLP-1 + GIP agonist | GLP-1 + GIP + Glucagon agonist | HGH fragment (lipolysis) |
| FDA status | Approved (diabetes + weight) | Approved (diabetes + weight) | Phase 3 trials | Not approved |
| Weight loss | 14.9% (68 wks) | 22.5% (72 wks) | 24.2% (48 wks) | Modest (limited data) |
| Route | Weekly SC injection | Weekly SC injection | Weekly SC injection | Daily SC injection |
| Max dose | 2.4 mg/week | 15 mg/week | 12 mg/week | 300 mcg/day |
| Titration time | 16 weeks | 20 weeks | 24 weeks | None |
| CV outcome data | Yes (SELECT: 20% MACE reduction) | Ongoing (SURPASS-CVOT) | No | No |
| GI side effects | Moderate-high | Moderate | Moderate | Minimal |
| Appetite suppression | Strong | Very strong | Very strong | None |
| Insulin sensitivity | Improves | Improves more | Improves most | No effect |
| Oral contraceptive interaction | No | Yes (reduces absorption) | Unknown | No |
| Pharmaceutical cost | ~$1,000–1,300/mo | ~$1,000–1,200/mo | N/A | N/A |
| Research-grade cost | ~$80–150/mo | ~$100–200/mo | ~$150–300/mo | ~$60–100/mo |
Understanding the Receptor Evolution
The progression from semaglutide to retatrutide illustrates how each additional receptor target adds metabolic benefit:
Single-Agonist: Semaglutide (GLP-1 Only)
What GLP-1 does: Suppresses appetite centrally, delays gastric emptying, enhances insulin secretion.
Semaglutide proved that targeting GLP-1 alone produces transformative weight loss. The STEP program showed consistent 15% body weight reduction. The SELECT trial proved cardiovascular protection beyond weight loss — a 20% reduction in heart attacks, strokes, and cardiovascular death.
The limitation: GLP-1 alone doesn’t address fat metabolism directly. Weight loss comes primarily from reduced caloric intake (eating less). The metabolic rate doesn’t increase.
Dual-Agonist: Tirzepatide (GLP-1 + GIP)
What GIP adds: Enhances fat metabolism in adipose tissue, improves beta-cell function, may buffer GI side effects.
Tirzepatide showed that adding GIP agonism produces ~50% more weight loss than GLP-1 alone (22.5% vs 14.9%). The GIP receptor contributes by improving how the body metabolizes fat — not just reducing intake, but improving the metabolic processing of stored energy.
SURPASS-2 showed tirzepatide 15 mg beat semaglutide 1 mg head-to-head in Type 2 diabetes. While the semaglutide dose was submaximal, the magnitude of difference (double the weight loss) exceeded what dose adjustment alone would explain.
Triple-Agonist: Retatrutide (GLP-1 + GIP + Glucagon)
What glucagon adds: Increases energy expenditure, promotes hepatic fat oxidation, mobilizes glycogen stores. This is the mechanism that separates retatrutide from everything else.
Retatrutide’s Phase 2 trial showed 24.2% weight loss at just 48 weeks — faster than tirzepatide achieved at 72 weeks. The glucagon receptor drives this: it increases the body’s metabolic rate, meaning retatrutide produces weight loss from both reduced intake AND increased expenditure.
The tradeoff: Retatrutide is still in Phase 3 trials. No FDA approval. No cardiovascular outcomes data. Available only as a research chemical.
Non-Incretin: AOD-9604 (HGH Fragment)
What it does: AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191). It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation) without the growth-promoting or diabetogenic effects of full HGH.
The reality check: AOD-9604 produces modest, targeted fat loss — not the dramatic 15–25% total body weight reductions seen with GLP-1 drugs. Clinical data is limited. It’s best suited as a body composition tool for people already near target weight, not as a primary weight loss treatment.
Choosing Your Protocol
Decision Framework
“I want maximum weight loss with the strongest evidence.” → Tirzepatide at 10–15 mg — FDA-approved, 22.5% weight loss, strong clinical evidence.
“I want weight loss with proven cardiovascular protection.” → Semaglutide at 2.4 mg — the only option with MACE reduction data (SELECT trial).
“I want the most aggressive weight loss and accept the investigational status.” → Retatrutide at 8–12 mg — 24.2% weight loss, but Phase 3 only.
“I don’t need dramatic weight loss — I want targeted fat loss.” → AOD-9604 — modest, targeted, minimal side effects, no appetite changes.
“I’m on oral birth control.” → Semaglutide — no oral contraceptive interaction. Tirzepatide reduces absorption.
“I want the cheapest option (research-grade).”
→ AOD-9604 ($60–100/mo) or semaglutide ($80–150/mo).
By Patient Profile
| Profile | Recommended | Rationale |
|---|---|---|
| BMI 30+, no diabetes | Tirzepatide 10–15 mg | Strongest weight loss, FDA-approved |
| BMI 30+, Type 2 diabetes | Tirzepatide or semaglutide | Both approved for T2D, tirzepatide has better glycemic control |
| BMI 27+, cardiovascular risk | Semaglutide 2.4 mg | Only option with proven MACE reduction |
| Near target weight, stubborn fat | AOD-9604 | Targeted fat loss without appetite/metabolic effects |
| Aggressive goals, risk-tolerant | Retatrutide 8–12 mg | Most weight loss, investigational status |
| Women on oral contraceptives | Semaglutide | No OC interaction (tirzepatide reduces absorption) |
The Muscle Loss Problem
Every GLP-1 weight loss drug causes lean mass loss alongside fat loss. This is the most important consideration for long-term outcomes:
| Drug | Lean Mass % of Weight Lost | Study |
|---|---|---|
| Semaglutide 2.4 mg | ~40% lean mass | STEP 1 DEXA substudy |
| Tirzepatide 15 mg | ~30% lean mass | SURMOUNT-1 body comp data |
| Retatrutide 12 mg | Data pending | Phase 2 substudy reported “significant fat mass reduction” |
Tirzepatide appears to preserve lean mass slightly better than semaglutide — possibly due to GIP’s effects on fat metabolism favoring fat-specific weight loss.
The universal protocol for every GLP-1 user:
- Resistance training 3–4x/week — non-negotiable
- Protein 1.2–1.6 g/kg/day — distributed across 3–4 meals
- Creatine 5g/day — cheap, effective muscle support
- Don’t crash calories — let the drug reduce appetite naturally
Side Effect Comparison
GI Side Effects
All incretin-based drugs cause GI distress. The frequency decreases with proper titration:
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | 40–50% | 25–35% | 25–35% |
| Diarrhea | 25–30% | 15–25% | 20–25% |
| Constipation | 20–25% | 10–15% | 15–20% |
| Vomiting | 15–20% | 10–15% | 10–20% |
AOD-9604 has essentially no GI side effects.
Metabolic Effects
| Effect | Semaglutide | Tirzepatide | Retatrutide | AOD-9604 |
|---|---|---|---|---|
| Insulin sensitivity | Improves | Improves more | Improves most | No effect |
| Fasting glucose | Improves | Improves more | Improves most | No effect |
| Blood pressure | Mild reduction | Mild reduction | Unknown | No effect |
| Heart rate | Mild increase | Mild increase | Mild increase | No effect |
| Thyroid risk | Boxed warning | Boxed warning | Under study | None known |
Cost Reality
Pharmaceutical (With Insurance)
If covered, copays range from $0–50/month. If not covered:
- Semaglutide (Wegovy): ~$1,300/month retail
- Tirzepatide (Zepbound): ~$1,060/month retail
- Compounded semaglutide: ~$200–400/month (being phased out as FDA enforces compounding restrictions)
Research-Grade (Out of Pocket)
| Peptide | Monthly Cost | Notes |
|---|---|---|
| Semaglutide | $80–150 | Requires reconstitution, math, injection experience |
| Tirzepatide | $100–200 | Same requirements |
| Retatrutide | $150–300 | Limited availability, less quality data on sources |
| AOD-9604 | $60–100 | Daily injection, shorter vial life |
Research-grade requires: purchasing from reputable vendors with CoA, reconstitution with BAC water, precise dosing with insulin syringes, and accepting that quality control is not pharmaceutical-grade.
The Long Game: What Happens After
All GLP-1 drugs are chronic treatments. Stopping leads to weight regain. This isn’t a “course of therapy” — it’s ongoing management of the biological drivers of obesity.
Options at maintenance:
- Continue indefinitely at the lowest effective dose
- Taper to a lower dose and maintain with lifestyle changes
- Cycle: use for 6–12 months, stop, re-initiate if weight regain exceeds a threshold
- Switch to a cheaper option for maintenance (e.g., research-grade semaglutide after stabilizing on pharmaceutical tirzepatide)
The muscle factor: Lean mass lost during treatment may not be fully regained during regain. This means repeated cycles of loss/regain progressively worsen body composition. This is the strongest argument for sustained treatment and aggressive muscle preservation during treatment.
Related Protocols
- Semaglutide Protocol — full dosing, titration, and management guide
- Tirzepatide Protocol — dual-agonist protocol with OC interaction details
- Retatrutide Protocol — triple-agonist investigational protocol
- AOD-9604 Protocol — non-GLP-1 targeted fat loss
- Reconstitution Calculator — exact unit counts for research-grade dosing
Frequently Asked Questions
What is the most effective weight loss peptide? +
Based on clinical trial data: retatrutide (24.2% body weight loss at 48 weeks) > tirzepatide (22.5% at 72 weeks) > semaglutide (14.9% at 68 weeks) > AOD-9604 (limited clinical data). However, retatrutide is not yet FDA-approved and is only available as a research chemical. Tirzepatide and semaglutide are both FDA-approved and widely available.
Which is better, Ozempic or Mounjaro? +
Mounjaro (tirzepatide) produces more weight loss than Ozempic (semaglutide) — approximately 22% vs 15% body weight loss at maximum doses. However, Ozempic has proven cardiovascular protection (SELECT trial, 20% MACE reduction) that Mounjaro has not yet demonstrated. If pure weight loss is the goal, Mounjaro is stronger. If cardiovascular risk is a concern, Ozempic has the evidence.
Is AOD-9604 as effective as semaglutide? +
No. AOD-9604 works through a completely different mechanism (lipolysis stimulation) and produces modest fat loss — not comparable to the 15–25% body weight reductions seen with GLP-1 drugs. AOD-9604 is best suited as a targeted fat loss supplement for people already at a healthy weight, not as a primary weight loss treatment.
Can I switch from semaglutide to tirzepatide? +
Yes. A washout period of 2–4 weeks is recommended to clear the previous drug. When starting tirzepatide, begin at the standard starting dose (2.5 mg) regardless of your previous semaglutide dose — the drugs target different receptors and dose equivalency is not straightforward.
Which weight loss peptide has the fewest side effects? +
AOD-9604 has the mildest side effect profile — no GI effects, no appetite changes, no metabolic effects. Among the GLP-1 class, semaglutide and tirzepatide have similar GI side effect rates. Tirzepatide may be slightly better tolerated at equivalent weight loss levels due to GIP buffering. Retatrutide's GI side effects are comparable to tirzepatide.